{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 14 of 169', 'List of abbreviations', 'AD', 'atopic dermatitis', 'ADA', 'anti-drug antibodies', 'AE', 'adverse event', 'AESI', 'adverse event of special interest', 'ALT', 'alanine aminotransferase', 'ANCOVA', 'analysis of covariance', 'AST', 'aspartate aminotransferase', 'BP', 'blood pressure', 'BSA', 'body surface area', 'CCL', 'C-C motif chemokine', 'CI', 'confidence interval', 'CMO', 'contract manufacturing organisation', 'CRA', 'clinical research associate', 'CRO', 'contract research organisation', 'C-SSRS', 'Columbia-Suicide Severity Rating Scale', 'CTR', 'clinical trial report', 'DLQI', 'Dermatology Life Quality Index', 'DMC', 'Data Monitoring Committee', 'DPP4', 'dipeptidyl peptidase 4', 'EASI', 'Eczema Area and Severity Index', 'EASI50', 'At least 50% reduction in EASI score', 'EASI75', 'At least 75% reduction in EASI score', 'EASI90', 'At least 90% reduction in EASI score', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'eDiary', 'electronic diary', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D-5L', 'EuroQoL 5-Dimension Health Questionnaire 5 Level', 'FU', 'follow-up visit', 'GCP', 'Good Clinical Practice', 'HADS', 'Hospital Anxiety and Depression Scale', 'HCP', 'healthcare professional', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 15 of 169', 'HQoL', 'health-related quality of life', 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation', 'ID', 'identification number', 'IEC', 'independent ethics committee', 'IGA', \"Investigator's Global Assessment\", 'IgE', 'immunoglobulin E', 'IL', 'interleukin', 'IMP', 'investigational medicinal product', 'IRB', 'institutional review board', 'IWRS', 'interactive web response system', 'LEO', 'LEO Pharma A/S', 'LOCF', 'last observation carried forward', 'nAB', 'neutralising antibodies', 'NRS', 'numeric rating scale', 'PDE-4', 'phosphodiesterase 4', 'PGI-B', 'Patient Global Impression of Bother', 'PGI-S', 'Patient Global Impression of Severity', 'PK', 'pharmacokinetics', 'POEM', 'Patient Oriented Eczema Measure', 'PRO', 'patient-reported outcome', 'Q2W', 'every 2 weeks', 'Q4W', 'every 4 weeks', 'SAE', 'serious adverse event', 'SC', 'subcutaneous', 'SCORAD', 'Scoring Atopic Dermatitis', 'SCORAD50', 'At least 50% reduction in SCORAD score', 'SF-36', '36-Item Short Form Health Survey', 'SoP', 'schedule of procedures', 'TCI', 'topical calcineurin inhibitor', 'TCS', 'topical corticosteroid', 'Th2', 'T-helper-2', 'TSQM', 'Treatment Satisfaction Questionnaire for Medication', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 16 of 169', 'ULN', 'upper limit of normal', 'UV', 'ultraviolet', 'WPAI-GH', 'Work Productivity and Activity Impairment - General Health', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}